Muscarinic receptor antagonists for overactive bladder

  title={Muscarinic receptor antagonists for overactive bladder},
  author={Paul Abrams and Karl Erik Andersson},
  journal={BJU International},
From time to time we publish a full review of drugs that are available for the treatment of common conditions. In this issue, the review is written by two of the leading authorities in the world, Paul Abrams and Karl‐Erik Andersson, on the topic of overactive bladder and antimuscarinic agents. This in‐depth review covers the entire range of questions that might be asked about this common area of interest. 
β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?
In this short review, the mechanisms of action, clinical efficacy, and adverse effect profiles of the two groups of drugs are compared and discussed.
Drugs for the treatment of overactive bladder syndrome: present and future (A Review)
Information on the principal directions of new drug development, in particular, β3-adrenoreceptor agonists, compounds affecting KCNQ/Kv7-channels, vitamin D receptors, etc., was summarized.
1091 Current pharmacotherapy of overactive bladder
This manuscript reviews the most important factors involved in the contemporary pharmacological treatment of OAB and suggests ways to individualize the medical treatment for the patient's characteristics and expectations.
Current pharmacotherapy of overactive bladder
This manuscript reviews the most important factors involved in the contemporary pharmacological treatment of OAB and recommends several new drugs for the treatment of overactive bladder.
Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity
Cognitive and CV effects are especially pertinent for the OAB patient who tends to be older with various comorbidities and is often taking multiple medications, so it is important to consider the risk/benefit balance of antimuscarinic agents when selecting OAB treatment.
Differential effects of selective and non‐selective muscarinic antagonists on gastrointestinal transit and bowel function in healthy women
The effects of non‐selective (fesoterodine) and M3‐ selective (solifenacin) antimuscarinics on gastrointestinal transit in healthy women are compared.
Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder
The pharmacology, efficacy, and adverse events of commonly used anticholinergic agents in treatment of overactive bladder syndrome are summarized.
Antimuscarinic Pharmacotherapy for Overactive Bladder
A variety of antimuscarinics are available for use in the treatment of overactive bladder and vary in their pharmacologic properties such as lipophilicity, molecular charge, and molecular size.
Solifenacin-induced acute psychosis: a case report
A case report of a 42-year-old male patient who had an acute psychotic attack as a result of solifenacin treatment for overactive bladder is presented in this article.


Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies.
A structurally diverse group of molecules, having varying receptor-selectivity profiles (non-selective, M3 selective, M2 selective,M2 sparing and M5 sparing), are in development for OAB and results of clinical trials with these drugs must be awaited before their therapeutic value can be accurately judged.
Trospium chloride: A quaternary amine with unique pharmacologic properties
Trospium chloride, available in Europe for more than 20 years and under review by the US Food and Drug Administration for the treatment of overactive bladder, is a quaternary amine that is minimally metabolized, not highly protein-bound, and theoretically should not cross the blood brain barrier.
Management of overactive bladder.
To the Editor: In his review of the management of overactive bladder (Feb. 19 issue),1 Dr. Ouslander states in Table 1 that cholinesterase inhibitors could theoretically contribute to detrusor